Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com

Equities researchers at StockNews.com started coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report released on Monday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Trading Down 4.0 %

Shares of NASDAQ CPIX opened at $1.69 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.28 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average price is $1.95 and its two-hundred day moving average price is $1.90. Cumberland Pharmaceuticals has a 52-week low of $1.43 and a 52-week high of $2.36. The stock has a market capitalization of $23.96 million, a P/E ratio of -3.84 and a beta of 0.16.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 15.87% and a positive return on equity of 6.84%. The firm had revenue of $9.35 million for the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Millennium Management LLC acquired a new position in Cumberland Pharmaceuticals in the fourth quarter valued at approximately $46,000. Bank of New York Mellon Corp acquired a new position in shares of Cumberland Pharmaceuticals during the third quarter valued at $142,000. Acadian Asset Management LLC grew its position in shares of Cumberland Pharmaceuticals by 27.8% during the first quarter. Acadian Asset Management LLC now owns 188,243 shares of the specialty pharmaceutical company’s stock worth $529,000 after acquiring an additional 40,949 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Cumberland Pharmaceuticals by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 644,763 shares of the specialty pharmaceutical company’s stock worth $1,818,000 after acquiring an additional 38,100 shares during the period. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.